# reload+after+2024-01-19 21:44:26.734067
address1§302 East Pettigrew Street
address2§Suite A-100
city§Durham
state§NC
zip§27701
country§United States
phone§919 314 5512
fax§480 393 5553
website§https://www.precisionbiosciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
fullTimeEmployees§115
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael  Amoroso', 'age': 45, 'title': 'President, CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 979041, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Alexander Kelly R.Ph.', 'age': 56, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 623576, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dario  Scimeca', 'age': 47, 'title': 'General Counsel & Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 576432, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jefferson J. Smith Ph.D.', 'age': 50, 'title': 'Co-Founder & Chief Research Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mei  Burris', 'title': 'Director of Investor Relations & Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bruce  Stevens', 'title': 'Vice President of Quality & Compliance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Maurissa  Messier', 'title': 'Senior Director of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Juli  Blanche', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Garrett  Gincley', 'title': 'Head of Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alan F. List M.D.', 'age': 68, 'title': 'Chief Medical Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.4
priceToSalesTrailing12Months§0.8678687
currency§USD
dateShortInterest§1702598400
forwardEps§-0.35
exchange§NCM
quoteType§EQUITY
shortName§Precision BioSciences, Inc.
longName§Precision BioSciences, Inc.
firstTradeDateEpochUtc§1553779800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3c610058-9f43-33c6-b360-7e8a0bce4509
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.0
targetLowPrice§2.0
targetMeanPrice§2.63
targetMedianPrice§2.75
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§2.484
grossMargins§1.0
ebitdaMargins§-1.36774
trailingPegRatio§None
